Pain agnosia

Summary

Pain agnosia (MONDO:0000675) is a disease. A subtype of mental disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pain agnosia
Mondo ID	MONDO:0000675
EFO	EFO:1001484
DOID	DOID:0060145
NCIT	C125664
UMLS	C0563625
MedGen	154351
GARD	0027550
Is cancer (heuristic)	no

Disease family

This is a subtype of mental disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › mental disorder › pain agnosia

Related subtypes (13): akinetopsia, cortical deafness, tactile agnosia, visual agnosia, psychosexual disorder, drug-induced mental disorder, alcohol-induced mental disorder, adjustment disorder, mood disorder, psychotic disorder, developmental disorder of mental health, anxiety disorder, disruptive behavior disorder

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 3 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Bupivacaine	Phase 3 (in late-stage trials)
Lidocaine	Phase 3 (in late-stage trials)
Ropivacaine	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 0.